Investment firms and brokerages such as
Canaccord Genuity and
Barclays have adjusted
Kenvue Inc's (KVUE) price targets, with Barclays reiterating its target to
$19. This comes after the company experienced a turbulent year of share price fluctuations. Many investors increased their positions in KVUE stock, including
Ossiam and
Legal & General Group Plc, while others, such as
Independent Franchise Partners LLP and
CI Investments Inc., reduced their holdings. Amid recent market happenings, Kenvue's valuation and pricing have come into focus, sparking debate among stakeholders. Another major event is KVUE's forthcoming merger with
Kimberly-Clark, valued at $48.7 billion. Notably, Kenvue has stated a plan to reduce its workforce by 3.5% in anticipation of this deal. Alongside these developments, there are ongoing legal challenges, particularly a Texas lawsuit concerning Tylenol safety, which Kenvue unsuccessfully tried to dismiss. Despite these hurdles, KVUE's Q4 results were robust, and company execs have secured more shares and RSUs. The company's profitability seems to be strengthening despite some headwinds in the consumer sector.
Kenvue KVUE News Analytics from Mon, 14 Jul 2025 07:00:00 GMT to Sat, 14 Mar 2026 11:21:02 GMT -
Rating 7
- Innovation 5
- Information 9
- Rumor -6
